Becker's Healthcare May 24, 2024
Mariah Taylor

FDA advisers have recommended the approval of Guardant Health’s blood test to detect colon or rectal cancers — but it also raised some concerns, NBC News reported May 23.

The panel voted 7-2 in favor of approving Gaurdant’s test, Shield. If the FDA does approve it, it will be the second blood-based test for colon cancer, competing with Epigenomics’ Epi proColon, which was approved in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Medical Devices, Patient / Consumer, Provider
Under RFK Jr., US Health Policy and FDA Operations May See Major Shifts
FDA AI Guidance - A New Era for Biotech, Diagnostics and Regulatory Compliance
Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
FDA clears sepsis test that significantly reduces life-or-death diagnosis time
Finally, FDA’s Final Word on Unapproved Use Communications

Share This Article